Leaders from Northwell Health’s Feinstein Institute for Medical Research, the U.S. Food and Drug Administration (FDA), and Boehringer Ingelheim recently led a symposium on the barriers and opportunities to increase patient diversity in clinical trials. Because medicines may affect people differently based on age, sex, and race, the diversity of clinical trial participants is important to…